CD40LG and autoimmune thrombocytopenic purpura: Nevertheless, although the investigation is in the very preliminary stages, there are new antibodies addressing the interaction between CD40 and CD154 that are candidates for use in ITP, and that are currently in ongoing phase-1 or 1/2 trials: letolizumab against CD154, and BI 655064 against CD40.